The natural antimicrobial peptide subtilosin acts synergistically with glycerol monolaurate, lauric arginate, and ε-poly-L-lysine against bacterial vaginosis-associated pathogens but not human lactobacilli

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1756-1761

  Noll, Katia Sutyak ^a,c   Prichard, Mark N ^b   Khaykin, Arkady ^a   Sinko, Patrick J ^a   Chikindas, Michael L ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Kraft Foods   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; EPSI POLY LEVO LYSINE; GLYCEROL MONOLAURATE; LAURIC ARGINATE; POLYPEPTIDE ANTIBIOTIC AGENT; SUBTILOSIN; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION (PARAMETERS); GARDNERELLA VAGINALIS; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; ARGININE; BACTERIA; BACTERIOCINS; DRUG SYNERGISM; FEMALE; GARDNERELLA VAGINALIS; HUMANS; KINETICS; LACTOBACILLUS; LAURATES; MICROBIAL SENSITIVITY TESTS; MONOGLYCERIDES; PEPTIDES, CYCLIC; POLYLYSINE; VAGINOSIS, BACTERIAL;

EID: 84858643473     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05861-11     Document Type: Article

References (44)

1. Amrouche T, Sutyak Noll K, Wang Y, Huang Q, Chikindas ML. 2010. Antibacterial activity of subtilosin alone and combined with curcumin, poly-lysine, and zinc lactate against Listeria monocytogenes strains. Probiotics Antimicrob. Proteins 2:250-257.
2. Amsel R, et al. 1983. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. 74:14-22. (Pubitemid 13221599)
3. Aroutcheva AA, Simoes JA, Behbakht K, Faro S. 2001. Gardnerella vaginalis isolated from patients with bacterial vaginosis and from patients with healthy vaginal ecosystems. Clin. Infect. Dis. 33:1022-1027. (Pubitemid 32907105)
4. Babasaki K, Takao T, Shimonishi Y, Kurahashi K. 1985. Subtilosin A, a new antibiotic peptide produced by Bacillus subtilis 168: isolation, structural analysis, and biogenesis. J. Biochem. 98:585-603. (Pubitemid 16216406)
5. Badaoui Najjar M, Kashtanov D, Chikindas ML. 2007. Epsilon-poly-L-lysine and nisin A act synergistically against Gram-positive food-borne pathogens Bacillus cereus and Listeria monocytogenes. Lett. Appl. Microbiol. 45:13-18. (Pubitemid 47012119)
6. Bakal G, Diaz A. 2005. The lowdown on lauric arginate. Food Qual. 12:54-61.
7. Bannatyne RM, Smith AM. 1998. Recurrent bacterial vaginosis and metronidazole resistance in Gardnerella vaginalis. Sex. Transm. Infect. 74: 455-456. (Pubitemid 29009106)
8. Chou T-C. 2006. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58:621-681. (Pubitemid 44403686)
9. Chou T-C. 2008. Preclinical versus clinical drug combination studies. Leuk. Lymphoma 49:2059-2080.
10. Code of Federal Regulations. 2010. Title 21. Food and drugs. Chapter I. Food an d Drug Administration. Subchapter B. Food for human consumption. Part 184. Direct food substances affirmed as generally recognized as safe. Subpart B. Listing of specific substances affirmed as GRAS. 21 CFR 184.1505-mono- and diglycerides. http://cfr.vlex.com /vid/184-1505-mono-and-diglycerides-19707498.
11. Eckert LO, Moore DE, Patton DL, Agnew KJ, Eschenbach DA. 2003. Relationship of vaginal bacteria and inflammation with conception and early pregnancy loss following in-vitro fertilization. Infect. Dis. Obstet. Gynecol. 11:11-17. (Pubitemid 36604817)
12. Falagas ME, Betsi GI, Athanasiou S. 2007. Probiotics for the treatment of women with bacterial vaginosis. Clin. Microbiol. Infect. 13:657-664. (Pubitemid 46909341)
13. Gibbs RS. 2007. Asymptomatic bacterial vaginosis: is it time to treat? Am. J. Obstet. Gynecol. 196:495- 496.
14. Goldenberg RL, Culhane JF, Johnson DC. 2005. Maternal infection and adverse fetal and neonatal outcomes. Clin. Perinatol. 32:523-529.
15. Haggerty CL, Hillier SL, Bass DC, Ness RB, PID Evaluation and Clinical Health Study Investigators. 2004. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin. Infect. Dis. 39:990-995. (Pubitemid 39313455)
16. Hashemi FB, Ghassemi M, Roebuck KA, Spear GT. 1999. Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis. J. Infect. Dis. 179:924-930. (Pubitemid 29159338)
17. Hashemi FB, Ghassemi M, Faro S, Aroutcheva A, Spear GT. 2000. Induction of human immunodeficiency virus type 1 expression by anaerobes associated with bacterial vaginosis. J. Infect. Dis. 181:1574-1580. (Pubitemid 30387747)
18. Hillier SL, et al. 1995. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N. Engl. J. Med. 333:1737-1742.
19. Kawulka KE, et al. 2004. Structure of subtilosin A, a cyclic antimicrobial peptide from Bacillus subtilis with unusual sulfur to alpha-carbon crosslinks: formation and reduction of alpha-thio-alpha-amino acid derivatives. Biochemistry 43:3385-3395. (Pubitemid 38391695)
20. Klaenhammer TR, Fremaux C, Ahn C, Milton K. 1993. Molecular biology of bacteriocins produced by Lactobacillus, p 151-180. In Hoover DG, Steenson LR (ed), Bacteriocins of lactic acid bacteria. Academic Press, Inc, New York, NY.
21. Liebetrau A, Rodloff AC, Behra-Miellet J, Dubreuil L. 2003. In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria. Antimicrob. Agents Chemother. 47:3667-3671. (Pubitemid 37345746)
22. Lin L, et al. 1999. The role of bacterial vaginosis in infection after major gynecologic surgery. Infect. Dis. Obstet. Gynecol. 7:169-174. (Pubitemid 29244772)
23. Lubbe MM, Botha PL, Chalkley LJ. 1999. Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa. Eur. J. Clin. Microbiol. Infect. Dis. 18:46-54. (Pubitemid 29531153)
24. Nelson DB, et al. 2007. First trimester bacterial vaginosis, individual microorganism levels, and risk of second trimester pregnancy loss among urban women. Fertil. Steril. 88:1396-1403. (Pubitemid 350047493)
25. Newton ER, Piper J, Peairs W. 1997. Bacterial vaginosis and intraamniotic infection. Am. J. Obstet. Gynecol. 176:672-677. (Pubitemid 27147182)
26. Nykanen A, Weckman K, Lapvetelainen A. 2000. Synergistic inhibition of Listeria monocytogenes on cold-smoked rainbow trout by nisin and sodium lactate. Int. J. Food Microbiol. 61:63-72.
27. Oakeshott P, Kerry S, Hay S, Hay P. 2004. Bacterial vaginosis and preterm birth: a prospective community-based cohort study. Br. J. Gen. Pract. 54:119-122. (Pubitemid 38190234)
28. Pechous R, Ledala N, Wilkinson BJ, Jayaswal RK. 2004. Regulation of the expression of cell wall stress stimulon member gene msrA1 in methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 48:3057-3063. (Pubitemid 38989175)
29. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:181-205. (Pubitemid 20377558)
30. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545. (Pubitemid 23072600)
31. Projan SJ, Brown-Skrobot S, Schlievert PM, Vandenesch F, Novick RP. 1994. Glycerol monolaurate inhibits the production of beta-lactamase, toxic shock toxin-1, and other staphylococcal exoproteins by interfering with signal transduction. J. Bacteriol. 176:4204-4209. (Pubitemid 24226455)
32. Sewankambo N, et al. 1997. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350:546-550. (Pubitemid 27348430)
33. Shima S, Matsuoka H, Iwamoto T, Sakai H. 1984. Antimicrobial action of episolon-poly-L-lysine. J. Antibiot. (Tokyo) 37:1449-1455.
34. Srinivasan S, Fredericks DN. 2008. The human vaginal bacterial biota and bacterial vaginosis. Interdiscip. Perspect. Infect. Dis. 2008:750479.
35. Strandberg KL, et al. 2010. Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Antimicrob. Agents Chemother. 54:597-601.
36. Sutyak KE, Wirawan RE, Aroutcheva AA, Chikindas ML. 2008. Isolation of the Bacillus subtilis antimicrobial peptide from the dairy productderived Bacillus amyloliquefaciens. J. Appl. Microbiol. 104:1067-1074. (Pubitemid 351393052)
37. Sutyak KE, et al. 2008. Spermicidal activity of the safe natural antimicrobial peptide subtilosin. Infect. Dis. Obstet. Gynecol. 2008:540758.
38. Sutyak Noll K, Sinko PJ, Chikindas ML. 2011. Elucidation of the molecular mechanism of action of the natural antimicrobial peptide subtilosin against the bacterial vaginosis-associated pathogen Gardnerella vaginalis. Probiotics Antimicrob. Proteins 3:41-47.
39. Taha TE, et al. 1999. HIV infection and disturbances of vaginal flora during pregnancy. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20: 52-59. (Pubitemid 29045470)
40. Thennarasu S, et al. 2005. Membrane permeabilization, orientation, and antimicrobial mechanism of subtilosin A. Chem. Phys. Lipids 137:38 -51.
41. Turovskiy Y, Chikindas ML. 2011. Zinc lactate and sapindin act synergistically with Lactocin 160 against Gardnerella vaginalis. Probiotics Antimicrob. Proteins 3:144-149.
42. Turovskiy Y, Sutyak Noll K, Chikindas ML. 2011. The aetiology of bacterial vaginosis. J. Appl. Microbiol. 110:1105-1128.
43. Vetter SM, Schlievert PM. 2005. Glycerol monolaurate inhibits virulence factor production in Bacillus anthracis. Antimicrob. Agents Chemother. 49:1302-1305. (Pubitemid 40463351)
44. Weir E. 2004. Bacterial vaginosis: more questions than answers. Can. Med. Assoc. J. 171:448. (Pubitemid 39179602)